Evidence map›Paper›PMID 40959254›Full record

ArticleACS medicinal chemistry letters2025

Optimization of Quinazolines for Inhibition of

Sam Spijkers-Shaw, Pradip K Gadekar, Baljinder Singh, Gaurav Kumar, Amrita Sharma, Benjamin Hoffman, Michael P Pollastri, Kojo Mensa-Wilmot, Lori Ferrins

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sam Spijkers-ShawPharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.ORCID https://orcid.org/0009-0005-0606-3533
Pradip K GadekarDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.ORCID https://orcid.org/0000-0002-9129-8812
Baljinder SinghDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.ORCID https://orcid.org/0000-0003-2828-5768
Gaurav KumarDepartment of Molecular Cell Biology, Kennesaw State University, Kennesaw, Georgia 30144, United States.
Amrita SharmaDepartment of Molecular Cell Biology, Kennesaw State University, Kennesaw, Georgia 30144, United States.
Benjamin HoffmanDepartment of Cellular Biology, University of Georgia, Athens, Georgia 30602, United States.
Michael P PollastriDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.ORCID https://orcid.org/0000-0001-9943-7197
Kojo Mensa-WilmotDepartment of Molecular Cell Biology, Kennesaw State University, Kennesaw, Georgia 30144, United States.
Lori FerrinsPharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.ORCID https://orcid.org/0000-0001-8992-0919

Funding

Optimization and Modes of Action of NEU-4438, a New Anti-trypanosome Lead DrugR01AI124046 · NIAID · NORTHEASTERN UNIVERSITY · PI FERRINS, LORI, MENSA-WILMOT, KOJO A. · 2016 to 2025
$6.0M
NIAID NIH HHS R01 AI124046
6 · The paper itself

Abstract

A large population of people remain at risk of contracting human African trypanosomiasis (HAT), which has significant health implications and leads to death. To prepare for future epidemics and provide alternative therapies in case of resistance to current treatment options for HAT, there is a need to continue developing novel therapeutics. Previously, we reported the repurposing and reoptimization of human kinase inhibitor, Lapatinib, toward inhibiting

Indexed as

Human African Trypanosomiasisphenotypic drug discoveryquinazolinesTrypanosoma brucei

Identifiers

PMID40959254
PMCPMC12434524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.